8-K: Natera Announces Strong Preliminary Results for Q4 and Full Year 2024, Revenue Jumps 56%

Natera reports preliminary unaudited results for Q4 and full year 2024, showcasing significant revenue growth and positive cash inflows.

Summary

• Natera, Inc. released preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
• Total revenues for Q4 2024 are expected to be approximately $472 million, a 52% increase compared to $311 million in Q4 2023.
• Full year 2024 total revenues are projected to be around $1.7 billion, up 56% from $1.1 billion in 2023.
• The company processed approximately 792,800 tests in Q4 2024, a 26.5% increase from 626,800 tests in Q4 2023.
• For the full year 2024, approximately 3,064,600 tests were processed, a 22.8% increase compared to 2,496,100 tests in 2023.
• Oncology tests in Q4 2024 reached approximately 150,800, including 144,500 clinical oncology tests, a 54.7% increase year-over-year.
• Full year 2024 saw approximately 528,200 oncology tests, including 498,300 clinical oncology tests, a 54.9% increase year-over-year.
• Natera achieved positive cash inflows of approximately $45.8 million in Q4 2024, compared to cash outflows of $60.8 million in Q4 2023.
• The company also achieved positive cash inflows of approximately $86.3 million for the full year 2024, compared to cash outflows of $267.1 million in 2023.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong revenue growth, increased test processing, and a significant improvement in cash flow. The company's performance exceeded expectations, indicating a strong market position and effective execution.

Positives

• Significant revenue growth in both Q4 and full year 2024.
• Substantial increase in test processing volume.
• Strong growth in oncology testing.
• Turnaround from cash outflows to positive cash inflows in both Q4 and full year 2024.
• Revenue exceeded the top end of the previous financial outlook by approximately $53 million.

Risks

• The preliminary financial results are unaudited and subject to change.
• Actual financial results may differ materially from the preliminary results.
• The company faces uncertainties in achieving its financial projections and goals.
• Natera has a history of net losses and anticipates continuing to incur net losses.
• Quarterly results may fluctuate from period to period.
• Estimates of market opportunity and forecasts of market growth may prove inaccurate.

Future Outlook

Natera plans to release its complete fourth quarter and full year 2024 financial results during its earnings call in February 2025 and will present additional business updates at the J.P. Morgan conference on January 15, 2025.

Management Comments

• Management uses non-GAAP cash flow as an indicator of the Company's operational cash generating capabilities.

Industry Context

Natera's focus on cell-free DNA and genetic testing aligns with the growing trend of personalized medicine and early disease detection in the healthcare industry.

Comparison to Industry Standards

• Companies like Exact Sciences and Guardant Health are also key players in the cancer diagnostics space, but Natera's diversified portfolio across oncology, women's health, and organ health provides a broader market reach.
• The 56% revenue growth significantly outpaces the average growth rate in the genetic testing market, suggesting strong market share gains.
• The shift to positive cash flow is a significant achievement, as many growth-stage diagnostics companies struggle with profitability.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and improved cash flow.
• Employees may benefit from the company's growth and success.
• Customers will continue to have access to Natera's genetic testing services.
• Suppliers may see increased demand for their products and services.
• Creditors may view Natera as a more creditworthy borrower due to its improved financial performance.

Next Steps

• Natera will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.
• Natera plans to release its complete fourth quarter and full year 2024 financial results during its earnings call in February 2025.

Key Dates